Biomarkers of Inflammation and Colorectal Cancer Risk

Overview

Journal Front Oncol

Specialty Oncology

Date 2025 Feb 21

PMID 39980561

Authors

Yuting Li

Yuexin Luo

Yue Ran

Furong Lu

You Qin

Affiliations

Soon will be listed here.

Abstract

Globally, colorectal malignancy ranks among the most prevalent forms of cancer and stands as the third principal cause of cancer-associated mortality. Recent studies indicate that inflammatory processes play a significant role in the initiation and advancement of various malignancies, colorectal cancer included. It explores inflammatory biomarkers, with C-reactive protein (CRP) being a key focus. While CRP's elevation during inflammation is linked to tumorigenesis, studies on its association with CRC risk are inconsistent, showing gender and methodological differences. Interleukin-6 (IL-6), TNF - α, and their receptors also play roles in CRC development, yet research findings vary. Adiponectin and leptin, secreted by adipocytes, have complex associations with CRC, with gender disparities noted. In terms of screening, non-invasive methods like fecal occult blood tests (FOBTs) are widely used, and combining biomarkers with iFOBT shows potential. Multi-omics techniques, including genomics and microbiomics, offer new avenues for CRC diagnosis. Overall, while evidence highlights the significance of inflammatory biomarkers in CRC risk prediction, larger prospective studies are urgently needed to clarify their roles due to existing inconsistencies and methodological limitations.

References

Yang Y, Gharaibeh R, Newsome R, Jobin C . Amending microbiota by targeting intestinal inflammation with TNF blockade attenuates development of colorectal cancer. Nat Cancer. 2021; 1(7):723-734. PMC: 7990316. DOI: 10.1038/s43018-020-0078-7. View

Mohd Salim N, Mussa A, Ahmed N, Ahmad S, Yean Yean C, Hassan R . The Immunosuppressive Effect of TNFR2 Expression in the Colorectal Cancer Microenvironment. Biomedicines. 2023; 11(1). PMC: 9856189. DOI: 10.3390/biomedicines11010173. View

Bongers G, Pacer M, Geraldino T, Chen L, He Z, Hashimoto D . Interplay of host microbiota, genetic perturbations, and inflammation promotes local development of intestinal neoplasms in mice. J Exp Med. 2014; 211(3):457-72. PMC: 3949565. DOI: 10.1084/jem.20131587. View

Stocks T, Lukanova A, Johansson M, Rinaldi S, Palmqvist R, Hallmans G . Components of the metabolic syndrome and colorectal cancer risk; a prospective study. Int J Obes (Lond). 2007; 32(2):304-14. DOI: 10.1038/sj.ijo.0803713. View

Kulbe H, Thompson R, Wilson J, Robinson S, Hagemann T, Fatah R . The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res. 2007; 67(2):585-92. PMC: 2679985. DOI: 10.1158/0008-5472.CAN-06-2941. View

Schreuders E, Ruco A, Rabeneck L, Schoen R, Sung J, Young G . Colorectal cancer screening: a global overview of existing programmes. Gut. 2015; 64(10):1637-49. DOI: 10.1136/gutjnl-2014-309086. View

Chandler P, Buring J, Manson J, Moorthy M, Zhang S, Lee I . Association between plasma adiponectin levels and colorectal cancer risk in women. Cancer Causes Control. 2015; 26(7):1047-52. PMC: 4466025. DOI: 10.1007/s10552-015-0590-8. View

Shen L, Zhou Y, He H, Chen W, Lenahan C, Li X . Crosstalk between Macrophages, T Cells, and Iron Metabolism in Tumor Microenvironment. Oxid Med Cell Longev. 2021; 2021:8865791. PMC: 7889336. DOI: 10.1155/2021/8865791. View

Kim H, Giovannucci E . Sex differences in the association of obesity and colorectal cancer risk. Cancer Causes Control. 2016; 28(1):1-4. DOI: 10.1007/s10552-016-0831-5. View

10.

Day L, Velayos F . Colorectal cancer screening and surveillance in the elderly: updates and controversies. Gut Liver. 2015; 9(2):143-51. PMC: 4351019. DOI: 10.5009/gnl14302. View

11.

Chan A, Ogino S, Giovannucci E, Fuchs C . Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterology. 2010; 140(3):799-808, quiz e11. PMC: 3049858. DOI: 10.1053/j.gastro.2010.11.041. View

12.

Ivancic M, Megna B, Sverchkov Y, Craven M, Reichelderfer M, Pickhardt P . Noninvasive Detection of Colorectal Carcinomas Using Serum Protein Biomarkers. J Surg Res. 2019; 246:160-169. PMC: 6957232. DOI: 10.1016/j.jss.2019.08.004. View

13.

Song M, Liu T, Liu H, Zhang Q, Zhang Q, Wang Y . Association between metabolic syndrome, C-reactive protein, and the risk of primary liver cancer: a large prospective study. BMC Cancer. 2022; 22(1):853. PMC: 9351132. DOI: 10.1186/s12885-022-09939-w. View

14.

Kimura M, Haisa M, Uetsuka H, Takaoka M, Ohkawa T, Kawashima R . TNF combined with IFN-alpha accelerates NF-kappaB-mediated apoptosis through enhancement of Fas expression in colon cancer cells. Cell Death Differ. 2003; 10(6):718-28. DOI: 10.1038/sj.cdd.4401219. View

15.

Zhou B, Shu B, Yang J, Liu J, Xi T, Xing Y . C-reactive protein, interleukin-6 and the risk of colorectal cancer: a meta-analysis. Cancer Causes Control. 2014; 25(10):1397-405. DOI: 10.1007/s10552-014-0445-8. View

16.

Tamakoshi K, Toyoshima H, Wakai K, Kojima M, Suzuki K, Watanabe Y . Leptin is associated with an increased female colorectal cancer risk: a nested case-control study in Japan. Oncology. 2005; 68(4-6):454-61. DOI: 10.1159/000086988. View

17.

Kim J, Lee J, Oh J, Chang H, Sohn D, Shin A . Circulating Interleukin-6 Level, Dietary Antioxidant Capacity, and Risk of Colorectal Cancer. Antioxidants (Basel). 2019; 8(12). PMC: 6943549. DOI: 10.3390/antiox8120595. View

18.

Tao S, Haug U, Kuhn K, Brenner H . Comparison and combination of blood-based inflammatory markers with faecal occult blood tests for non-invasive colorectal cancer screening. Br J Cancer. 2012; 106(8):1424-30. PMC: 3326680. DOI: 10.1038/bjc.2012.104. View

19.

Vogtmann E, Hua X, Zeller G, Sunagawa S, Voigt A, Hercog R . Colorectal Cancer and the Human Gut Microbiome: Reproducibility with Whole-Genome Shotgun Sequencing. PLoS One. 2016; 11(5):e0155362. PMC: 4865240. DOI: 10.1371/journal.pone.0155362. View

20.

Haynes K, Beukelman T, Curtis J, Newcomb C, Herrinton L, Graham D . Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum. 2012; 65(1):48-58. PMC: 3778442. DOI: 10.1002/art.37740. View